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ABSTRACT
G-protein-coupled receptor 81 (GPR81) functions as a receptor for lactate 
and plays an important role in the regulation of anti-lipolytic effects in adipocytes. 
However, to data, a role for GPR81 in the tumor microenvironment has not been 
clearly defined. Here, GPR81 expression in breast cancer patients and several breast 
cancer cell lines was significantly increased compared with normal mammary tissues 
and cells. GPR81 knockdown resulted in impaired breast cancer growth and led to 
apoptosis both in vitro and in vivo. Furthermore, the inhibition of GPR81 signaling 
suppressed angiogenesis through a phosphoinositide 3-OH kinase (PI3K)/Akt-cAMP 
response element binding protein (CREB) pathway, which led to decreased production 
of the pro-angiogenic mediator amphiregulin (AREG). Overall, these findings identify 
GPR81 as a tumor-promoting receptor in breast cancer progression and suggest 
a novel mechanism that regulates GPR81-dependent activation of the PI3K/Akt 
signaling axis in tumor microenvironment.
INTRODUCTION
Breast cancer is the leading cause of cancer-related 
mortality in females worldwide [1]. Our understanding of 
the molecular mechanisms of breast cancer has improved 
in the previous two decades; however, the prognosis and 
treatment of breast cancer, particularly in advanced cases, 
has not been significantly improved [2, 3]. Breast cancer 
is a heterogeneous disease defined by different activating 
mutations, epigenetic modifications and aberrant signaling 
pathways. Thus, a more detailed understanding of the 
molecular mechanisms underlying the breast cancer 
progression will provide new insight into individual 
treatment of breast cancer.
G-protein-coupled receptors (GPCRs) comprise 
seven-transmembrane proteins that regulate important 
physiological processes, through the coordinated action of 
their signaling pathways [4–6]. Altered gene expression 
and dysregulated GPCR signaling have been recognized as 
hallmarks of cancer [7, 8]. Abnormal expression of specific 
GPCRs on cell membranes stimulates the continual 
unregulated proliferation and triggers intracellular 
signal transductions that ultimately lead to the growth of 
cancer cells, induction of angiogenesis and metastasis. 
Approximately 50% of marketed pharmaceuticals target 
human GPCRs or their signaling pathways; however, 
a limited number of these receptors are used as cancer 
therapeutic targets [9, 10]. A tremendous amount of efforts 
have been made to so far aiming at exploiting therapeutic 
applications of the remaining family members, including 
more than 140 orphan GPCRs whose endogenous ligands 
or functions have yet to be unidentified [11].
Recently, an increasing number of orphan GPCRs 
have been demonstrated to be activated by metabolic 
intermediates or energy substrates [12, 13]. In particular, 
the GPR81 family of receptors consists of three members 
that are primarily expressed in adipocytes (GPR109a, 
GPR109b and GPR81), and activation by their respective 
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agonists (3-hyfroxybutyrate, 3-hydroxyoctanoate, and 
lactate) inhibits adipocyte lipolysis [14]. It has been 
proposed to have an important role in metabolic disorders, 
such as dyslipidemia and type 2 diabetes [15, 16]. In 
tumor microenvironment, malignant cancer cells with 
enhanced glucose uptake export lactate as a by-product 
of glycolysis. However, the expression of GPR81 and its 
role in breast cancer progression have not been previously 
reported in the context of the tumor microenvironment.
Here, we describe the role of GPR81 in the 
pathogenesis of human breast cancer. We provide 
evidence that GPR81 promotes proliferation via the 
inhibition of apoptosis and stimulates the secretion of 
several angiogenic factors in a PI3K/Akt-CREB signaling 
pathway-dependent manner. Taken together, our findings 
suggest that GPR81 functions to promote cancer cell 
survival and angiogenesis and represents a potential target 
for breast cancer treatment.
RESULTS
GPR81 is aberrantly expressed in breast cancer
To determine GPR81 expression in breast cancer, 
we analyzed the GPR81 mRNA levels in various breast 
cancer cell lines. GPR81 mRNA was detected in 8 of 
11 (72%) breast cancer cells compared with a normal 
mammary epithelial cell line, MCF10A (Figure 1A). 
Among these cancer cell lines, MCF7 cells, which highly 
expressed GPR81 (a 22-fold increase compared with 
MCF10A cells), were further investigated. Moreover, the 
GPR81 mRNA levels correlated with the protein levels, 
as indicated by immunofluorescence. Increased GPR81 
protein levels were identified in MCF7 cells, while 
decreased levels were found in MCF10A cells (Figure 
1B). For clinical relevance, we examined the GPR81 
expression in archived breast cancer tissues and normal 
breast tissues using quantitative polymerase chain reaction 
(qPCR). As shown in Figure 1C, the GPR81 expression in 
cancer tissues was significantly increased compared with 
the adjacent noncancerous tissues (P<0.001). In addition, 
an analysis of a large cancer dataset by the cBioPortal 
[17, 18] indicated that breast cancers showed the greatest 
number of genomic copies of GPR81 compared with other 
cancer types (Supplementary Figure S1A). Interestingly, 
increased GPR81 expression was correlated with the 
estrogen receptor (ER)-positive status of breast cancer 
patients (Supplementary Figure S1B), which suggests that 
GPR81 may comprise an important regulator or prognostic 
marker of breast cancer.
GPR81 promotes breast cancer cell proliferation 
and inhibits apoptosis in vitro
To investigate the physiological role of GPR81 
in breast cancer progression, we generated stable 
knockdown cell lines (MCF7-shGPR81 and MCF7-
shCTL) using lentiviruses that harbored shRNA. Two 
different shRNA sequences significantly reduced the 
GPR81 expression compared with MCF7-shCTL cells 
at the mRNA and protein levels (Supplementary Figures 
S2A and S2C). To assess whether GPR81 plays a role 
in breast cancer cell proliferation, we subsequently 
monitored the cell proliferation rate for 7 days at the 
indicated conditions (Figure 2A). Proliferation was 
significantly reduced to less than half in MCF7-shGPR81 
cells under growth and low-serum conditions (Figure 
2A). To determine whether the requirement for GPR81 
for growth was a general feature of breast cancer cell 
lines, we suppressed GPR81 expression in an additional 
cell line, T47D (Supplementary Figure S2B). The T47D-
shGPR81 cell lines grew more slowly than those infected 
with control shRNA in both growth and low-serum 
conditions (Supplementary Figure S3). These findings 
indicate that GPR81 increases the proliferation of breast 
cancer cells.
We subsequently investigated whether the GPR81 
knockdown-induced loss of breast cancer viability 
resulted from apoptosis. As shown in Figure 2B, 
GPR81 knockdown in MCF7 cells led to an increased 
percentage of apoptosis (from 11.3% to 29.8%, 
Annexin-V (+) cells) under the growth condition 
(Figure 2B). Akt functions as a central regulator of cell 
survival by inhibiting apoptosis and promoting cell 
survival [19, 20]. Consistently, the Akt phosphorylation 
level was significantly decreased in MCF7-shGPR81 
cells and increased the cleavage of poly (ADP-
ribose) polymerase (PARP) and caspase-9, markers 
of apoptosis, in MCF7-GPR81 cells (Figure 2C). The 
opposite results were identified when the addition of 
the pan-caspase inhibitor Z-VAD-FMK enhanced the 
tumor cell growth exhibited in GPR81-knockdown 
cells (Supplementary Figure S4). Taken together, our 
findings indicate that the GPR81/Akt pathway is critical 
for breast cancer cell survival and apoptosis.
GPR81 promotes breast cancer cell migration 
and invasion
To investigate the role of GPR81 in breast cancer 
metastasis, we measured the migratory and invasive 
capacity of GPR81-knockdown MCF7 cells. Using a 
Transwell assay, we demonstrated that the migration of 
GPR81-knockdown cells was reduced by 50% compared 
with control cells (Supplementary Figure S5A). In 
addition, using a Matrigel-coated Transwell invasion 
assay, we determined that the number of MCF7-shGPR81 
cells that invaded through the Matrigel was significantly 
decreased compared with control cells (Supplementary 
Figure S5B). These findings indicated that GPR81 
functions as a regulatory factor that promotes breast 
cancer cell aggressiveness.
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GPR81 activation promotes angiogenesis in vitro
Angiogenesis plays an essential role in tumor 
growth and metastasis [21, 22]. Tumor cells stimulate 
angiogenesis via the secretion of several pro-angiogenic 
factors, which promote tumor survival and metastasis 
through autocrine or paracrine signaling pathways. 
Thus, we investigated the effects of GPR81 activation 
on the regulation of cytokine and angiogenic factor 
expression in cancer cells. Among a panel of factors 
related to angiogenesis six factors were significantly 
decreased in the conditioned media (CM) from MCF7-
shGPR81 cells compared with MCF7-shCTL cells; 
these factors included amphiregulin (AREG), platelet-
derived growth factor (PDGF-AA), serpin peptidase 
inhibitor clade E (Serpin E1), serpin peptidase inhibitor 
clade F (Serpin F1), plasminogen activator (urokinase, 
uPA) and vascular endothelial growth factor (VEGF; 
Figure 3A).
Among the 6 factors regulated by GPR81, the 
AREG levels exhibited the greatest difference between 
the MCF7-shCTL and MCF7-shGPR81 cells at both 
the protein and mRNA levels (Figures 3B and 3C). 
AREG has been reported to stimulate cell proliferation 
and mammary gland development by acting as a ligand 
for the epidermal growth factor receptor (EGFR) [23, 
24]. We initially aimed to determine whether tumor-
derived AREG regulated the function of endothelial 
cells. We found that AREG promoted endothelial cell 
proliferation and migration in a dose-dependent manner 
(Supplementary Figures S6A and S6B). Furthermore, 
AREG dose- and time-dependently induced EGFR, Akt 
and ERK1/2 MAPK phosphorylation (Supplementary 
Figures S6C and S6D). AREG significantly induced 
Figure 1: GPR81 is highly expressed in breast cancer. A. Quantitative PCR (qPCR) analyses of GPR81 mRNA expression 
in eleven human breast cancer cell lines and immortalized normal human mammary epithelial cells (MCF10A). The relative mRNA 
expression of GPR81 is presented as the mean±SEM; n≥3. B. GPR81 immunofluorescence staining of MCF10A or MCF7 cells (Green). 
Nuclei were counterstained with DAPI. The scale bar represents 20 µm. C. Relative mRNA expression of GPR81 in breast cancer (n=60) 
versus normal (n=20) tissues (unpaired two-tailed t-test).
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in vitro endothelial cell (HUVECs) tube formation (Figure 
3D) in a dose-dependent manner. To investigate the effect 
of tumor-derived AREG on endothelial cells, we incubated 
HUVECs with CM obtained from MCF7-shCTL cells 
and MCF7-shGPR81 cells. Consistently, the cells treated 
with the CM obtained from MCF7-shCTL cells showed 
efficient endothelial cell tube formation, whereas cells 
treated with the CM obtained from the MCF7-shGPR81 
cells showed significantly impaired endothelial cell tube 
formation (Figure 3E). Strikingly, CM-induced tube 
formation was significantly decreased by neutralizing 
AREG with an anti-AREG antibody (Figure 3E). These 
findings indicate that GPR81 stimulates AREG production 
in MCF7 cells and promotes tumor angiogenesis in 
a paracrine loop. To determine the effects of AREG 
signaling on breast cancer cells, we subsequently treated 
MCF7-shCTL and MCF7-shGPR81 cells with AREG. 
AREG promoted cell proliferation and migration in a 
dose-dependent manner in the MCF7-shCTL and MCF7-
shGPR81 cell lines (Supplementary Figures S7A and 
S7B). Consistently, the phosphorylated-EGFR and -Akt 
levels were slightly restored in AREG-stimulated MCF7-
shGPR81 cells (Supplementary Figure S7C). Taken 
together, these findings suggest that the GPR81-induced 
AREG autocrine and paracrine loop plays a critical role in 
breast cancer progression.
Figure 2: GPR81 knockdown impairs cell proliferation and increases apoptosis. A. MCF7-shCTL or shGPR81 cells were 
seeded in 96-well plates and cultured under growth (10% serum, left) or low-serum (2% serum, right) conditions for 7 days. These data were 
condensed into quantifiable metrics using algorithms to generate a kinetic proliferation curve. The data are expressed as the mean±SEM; 
n≥3. *, P < 0.05 for the difference between cells that expressed control shRNA and cells with GPR81 shRNA. B. Flow cytometry (FACS) 
analysis of apoptosis in MCF7-shCTL and MCF7-shGPR81 cells. Early apoptosis, Annexin V+/ propidium iodide (PI)-cells; late apoptosis, 
Annexin V+/PI+cells. C. Immunoblot analysis of Akt phosphorylation, PARP and caspase-9 cleavage at 24 h in the indicated conditions.
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GPR81 signaling induces angiogenesis via PI3K/
Akt pathway activation
To define the molecular mechanism by which 
GPR81 modulates AREG transcription, we analyzed 
the transcriptional regulatory elements in the AREG 
promoter region. The CREB binding site is highly 
conserved in AREG orthologues from several different 
species (Figure 4A), and AREG may be regulated by 
CREB activation. To establish AREG as a specific CREB 
target gene, we performed chromatin immunoprecipitation 
(ChIP) using an anti-CREB antibody and primer designed 
Figure 3: GPR81 activation promotes angiogenesis in primary human endothelial cells in vitro. A. Angiogenic factor 
array of the conditioned media (CM) from MCF7-shCTL (top) and MCF7-shGPR81 cells (bottom) (left). The relative signal 
intensity of the indicated factor is presented (right). The data are expressed as the mean±SEM; n≥3. B. AREG levels in the 
CM from MCF7-shCTL and MCF7-shGPR81 cells were measured via an enzyme-linked immunosorbent assay (ELISA). *, 
P<0.005. The data are expressed as the mean±SEM; n≥3. C. AREG mRNA expression was measured via quantitative real-
time PCR. All data are shown as the mean±SEM; n≥3; *, P<0.005. D. Representative images of HUVEC tube formation. 
HUVECs were treated with recombinant AREG at different concentrations. The bars represent the mean value of the tube 
area±SEM from five independent experiments (right). Scale bar, 20 µm; **, P<0.01. E. Representative images of HUVEC 
tube formation in the indicated conditions. Tube formation was quantified in five randomly selected fields (right). Scale bar, 
20 µm; *, P<0.01; **, P<0.05.
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to detect the promoter of AREG. Compared with control 
cells, the baseline binding of CREB to AREG promoters 
was reduced in GPR81-knockdown cells (Figure 4B). 
Consistent with this result, CREB phosphorylation was 
significantly reduced in MCF7-shGPR81 cells (Figure 
4C). Therefore, the GPR81-mediated signaling pathway 
directly activates the AREG promoter via the transcription 
factor CREB.
CREB is a transcription factor activated by a diverse 
extracellular signals [25]. The well-established mechanism 
Figure 4: GPR81 signaling promotes angiogenesis via PI3K/Akt-CREB pathway activation. A. CREB binding sites were 
enriched in the AREG promoter region. B. ChIP assay was performed with MCF7-shCTL and MCF7-shGPR81 cells using an anti-CREB 
antibody. AREG transcript levels were measured via qPCR analysis (*, P<0.01). The mean±SEM of three independent experiments is shown. 
C. MCF7-shCTL or MCF7-shGPR81 cells were seeded in 6-well plates and were treated with or without serum. CREB phosphorylation 
levels were measured via western blotting. D. Western blot analysis of cell lysates from MCF7-shCTL and MCF7-shGPR81 cells was 
used to detect phosphorylation of PI3K pathway components. β-actin was used as a loading control. E. AREG mRNA expression and 
protein secretion were measured via qPCR and ELISA assays, respectively. The data are expressed as the mean±SEM of three independent 
experiments; *, P<0.05;**, P<0.01. F. Representative images of HUVEC tube formation (left). HUVECs were treated with MCF7-shCTL 
CM and MCF7-shGPR81 CM with or without LY294002. Scale bar, 20 µm. Tube formation was quantified in five randomly selected fields. 
The bars represent the mean values of the tube area±SEM of five independent experiments. **, P<0.05 (right).
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of CREB activation is the cAMP/ protein kinase A (PKA) 
pathway. To determine whether PKA is the upstream 
molecule responsible for CREB activation, we measured 
the cAMP levels in MCF7-shCTL and MCF7-shGPR81 
cells. However, we did not identify a significant difference 
in cAMP production between the MCF7-shCTL and 
MCF7-shGPR81 cells (data not shown). Therefore, we 
hypothesized that GPR81-induced CREB activation is 
regulated by another signaling pathway.
CREB activation may also be activated by PI3K/
Akt; thus, our next step was to determine whether 
PI3K/Akt signaling was involved in GPR81-induced 
activation of CREB. As shown in Figure 4D, the basal 
phosphorylation of Akt and CREB were increased in 
MCF7-shCTL cells, whereas GPR81 depletion by shRNA 
blocked the activation of Akt and CREB. Consistent with 
this result, the treatment of LY294002, a PI3K inhibitor, 
potently reduced Akt and CREB activation both in MCF7-
shCTL and MCF7-shGPR81 cells (Figure 4D). Moreover, 
LY294002 treatment inhibited the induction of AREG 
in MCF7-shCTL and MCF7-shGPR81 cells at both the 
mRNA and protein levels (Figure 4E). We subsequently 
performed a tube formation assay to determine whether 
GPR81-mediated angiogenesis was dependent on the 
PI3K/Akt-CREB pathway. As a result, GPR81-induced 
angiogenesis was inhibited in the presence of LY294002 
(Figure 4F). Taken together, our findings suggest that 
angiogenesis enhanced by GPR81 signaling is mediated 
by the PI3K/Akt-CREB pathway via the regulation of 
angiogenic factors.
GPR81 promotes orthotopic breast tumor 
growth and angiogenesis
To determine the effect of GPR81 signaling on 
breast cancer growth and angiogenesis, we generated an 
orthotopic xenograft mouse model. Two populations of 
MCF7 cells (MCF7-shCTL and MCF7-shGPR81) were 
orthotopically injected into the mammary fat pads of 
athymic nude mice, and tumor growth was monitored. As 
expected, the primary tumors from MCF7-shGPR81 mice 
grew at a significantly slower rate and were smaller in size 
compared with the MCF7-shCTL animals (Figures 5A and 
5B). Consistently, histological examination indicated that 
the proliferation rates (Ki-67 labeling index) of the tumors 
from the mice injected with MCF7-shGPR81 cells were 
substantially decreased compared to those of tumors from 
mice injected with the MCF7-shCTL cells (Figure 5C). In 
addition, the proportion of apoptotic cells was increased 
in the tumor region of the MCF7-shGPR81-injected mice 
(Figure 5D). Collectively, these findings suggest that 
GPR81 is critical in modulating survival and apoptosis in 
breast cancer cells in vivo.
We subsequently aimed to investigate the 
angiogenic effects of GPR81 in vivo. Compared with 
MCF7-shCTL-injected mice, MCF7-shGPR81-injected 
mice exhibited substantial reductions in microvascular 
density (CD31 positivity; Figures 6A, middle bottom and 
6B), which indicates that GPR81 signaling promoted new 
blood vessel formation. Moreover, the AREG expression 
was significantly decreased in MCF7-shGPR81 tumors 
(Figures 6A, right bottom and 6C), and the AREG 
protein levels were also decreased in the serum of the 
MCF7-shGPR81 mice (Figure 6D). Taken together, these 
findings strongly suggest that GPR81 signaling enhances 
breast tumor growth in vivo likely through the inhibition 
of apoptosis and enhanced angiogenesis via AREG 
expression stimulation (Figure 7).
DISCUSSION
In this study, we report a previously unknown role 
for GPR81 in breast cancer progression. In the tumor 
microenvironment, increased lactate levels significantly 
activated GPR81, which leads to the activation of cell 
survival signaling and the production of the angiogenic 
factor AREG to promote angiogenesis and cancer cell 
growth via PI3K/Akt pathway. Our results indicate that 
GPR81 is a putative tumor-promoting gene that promotes 
angiogenesis and the survival of breast cancer cells in 
tumor microenvironment.
Endogenous GPR81 expression has been identified 
in the adipocytes of humans and mice; however, it is 
also present at low levels in various normal cells such as 
skeletal muscle and liver [26, 27]. Here, we demonstrated 
that GPR81 was expressed in the normal human mammary 
epithelium at very low levels. Strikingly, we identified 
significantly increased GPR81 expression in a substantial 
cohort of human breast cancer tissues [28] and a panel 
of breast cancer cell lines. In addition, the GPR81 
expression levels significantly correlated with the clinical 
characteristics of breast cancer, particularly ER status 
(Supplementary Figure S1B). This is consistent with our 
observation that ER-positive breast cancer cells (MCF7 
and T47D) expressed GPR81 at a higher level (Figure 
1A). Recent studies have identified GPR81 expression in 
several cancer cell types, including colon, lung and breast 
cancers [29, 30], which is in agreement with the GPR81 
expression pattern identified in the current study (Figures 
1A-1C). These findings suggest that GPR81 may be a 
prognostic marker and GPR81-mediated signaling could 
play a key role in the progression of breast cancer.
Altered cellular metabolism is a hallmark of cancer 
(the Warburg effect) and the lactate concentrations range 
from 5 to 20 mmol/L in the tumor microenvironment 
[31]. Although lactate has generally been considered as 
a by-product of metabolism, recent evidence suggest that 
lactate functions as an active metabolite and stimulates 
signaling pathway [32, 33]. We investigated whether 
lactate is involved in GPR81-mediated signaling pathway 
in high lactate concentration. Exogenous lactate did 
not stimulate the cell viability of MCF7-shCTL or 
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MCF7-shGPR81 cells (Supplementary Figure S8A). 
Moreover, exogenous lactate had no effect on the Akt 
phosphorylation of either MCF7-shCTL and MCF7-
shGPR81 cells (Supplementary Figure S8C). However, 
the growth of MCF10A cells transfected with myc-tagged 
GPR81 more increased than those of cells transfected with 
empty vector (Supplementary Figure S8B). Furthermore, 
exogenous lactate slightly increased the cell viability of 
MCF10A-myc-GPR81 cells. Therefore, breast cancer cells 
were not sensitive to exogenous lactate as a ligand, and 
Figure 5: GPR81 depletion blocks breast cancer growth and survival in xenograft tumors. A. Tumor volumes of MCF7-
shCTL (n=10) and MCF7-shGPR81 (n=10) xenografts were measured over a period of 50 days after cell inoculation. The data are expressed 
as the mean volume±SEM; **, P<0.05. B. Representative images of the xenograft tumors (top) and tumor weights (bottom) at 50 days after 
tumor cell injection. The data are expressed as the mean weight±SEM; **, P<0.05. C. Ki-67-positive cell numbers were determined in 
individual xenograft tumors. Representative IHC staining of the tumors from each group of mice is presented (left). The bars represent the 
mean percentage of Ki-67-positive cells±SEM; *, P<0.01 compared with MCF7-shCTL mice (right). D. Representative images of TUNEL 
staining in tumor tissues from xenografts (left). The bars represent the mean percentage of TUNEL-positive cells (apoptotic cells)±SEM; 
**, P<0.05 compared with MCF7-shCTL mice (right).
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GPR81 may be constitutively activated in the high lactate 
concentration of tumor microenvironment.
The activation of GPR81 subsequently inhibits 
lipolysis and β-oxidation and, as recently demonstrated, 
increases the mRNA expression levels of genes critical 
for lactate metabolism [29]. These metabolic changes 
may partially influence cancer cell survival. However, 
increased lactate levels could act as a signal to activate 
its specific receptor, not as a metabolic fuel. In current 
study, the loss of GPR81 in MCF7 cells led to a loss of 
viability and increased apoptosis in vitro and in vivo. One 
well-established pathway, the PI3K/Akt pathway, mediates 
pro-survival signals in various types of cancers [20]. In 
particular, Akt is involved in the inhibition of apoptosis via 
the phosphorylation of pro-apoptotic molecules, e.g., Bad 
or caspase-9, or the modulation of transcription factors, 
such as c-Raf [34]. At the molecular level, constitutive 
Akt activation (phosphor-Akt) was suppressed, and PARP 
cleavage and caspase-9 activity were increased in MCF7-
shGPR81 cells, indicating an apoptotic signature. GPR81 
knockdown-induced apoptosis was reversed, in part, by 
treatment with a pan-caspase inhibitor (Supplementary 
Figure S4). Thus, PI3K/Akt inhibition-induced caspase-
dependent apoptosis appears to comprise a key factor in 
the GPR81-mediated cell survival pathway.
Angiogenesis, the process of neo-vessels formation, 
has a key role in breast cancer growth and progression 
[35]. Angiogenic switch, the shift in the balance between 
Figure 6: Effects of GPR81 silencing on angiogenesis in an orthotopic breast cancer model. A. Representative microscopic 
images of tumor sections stained with H&E (left), CD31 (middle), and AREG (right) are presented. The scale bar represents 50 µm. 
B. Blood vessels (CD31-positive area) were quantified in tumor sections from xenografts. The data are expressed as the mean±SEM; 
*, P<0.05. C. AREG expression was quantified in tumor sections from the MCF7-shCTL and MCF7-shGPR81 mice. The data are expressed 
as the mean±SEM; **, P<0.05. D. Levels of human AREG in the blood obtained from the xenograft model. The data are expressed as the 
mean±SEM **, P<0.01.
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proangiogenic and antiangiogenic factors in favor of 
pro-angiogenesis, applies to almost types of solid tumors 
[36, 37]. Here, we found that AREG is a critical factor 
in GPCR-induced angiogenesis. AREG is a ligand of 
EGFR [38] that plays a central role in mammary gland 
development and branching morphogenesis in organs [39]. 
AREG plays a central role in numerous physiological and 
pathological processes, especially in cancer progression 
and development [40]. Here, we showed that GPR81 
signaling enhanced angiogenesis via the induction of 
several genes involved in angiogenesis including AREG in 
vitro and in vivo. Furthermore, we demonstrated cancer-
derived AREG partially promoted breast cancer growth and 
migration via an autocrine AREG/EGFR signaling pathway 
(Supplementary Figures S7). These findings suggested that 
GPR81 signaling-induced AREG promoted tumor cells 
to switch to an angiogenic phenotype, thereby leading to 
tumor progression in an autocrine/paracrine manner.
Our results also revealed the molecular mechanisms 
that underlie GPR81-induced angiogenesis. CREB 
plays important roles in the development of malignant 
phenotypes, and its aberrant activation has been 
demonstrated in various cancer cell types [41]. Numerous 
proangiogenic genes, such as VEGF and endothelin-1, 
are transcriptionally regulated by the CREB pathway [42, 
43]. We demonstrated that GPR81 activation promoted 
CREB phosphorylation in MCF7 cells, which is essential 
for the translocation of active CREB to the nucleus. 
Furthermore, blocking CREB activation completely 
abrogated the GPR81 signaling-induced production of 
AREG and angiogenesis. CREB activation is mediated 
by several upstream signaling pathways [41]. cAMP-
dependent protein kinase phosphorylated CREB is a well-
known signaling pathway; however, GPR81 activation did 
not change the concentration of cAMP in our cell system 
(data not shown). In contrast, our data suggested the 
PI3K/Akt pathway was indeed activated by GPR81. The 
suppression of PI3K/Akt signaling abrogated the GPR81-
induced effects on CREB activation and subsequently 
inhibited AREG expression and angiogenesis. These data 
support that the PI3K/Akt-CREB pathway contributes to 
the tumor-associated angiogenesis mediated by aberrant 
GPCR signaling in tumor microenvironment.
In conclusion, our current results show that 
GPR81 functions as a tumor-promoting receptor that 
senses extracellular lactate in human breast cancer. 
GPR81 signaling activation promotes cell survival and 
angiogenesis, mainly by stimulating Akt activation 
and proangiogenic factor production, respectively. 
Therefore, our findings provide extended mechanistic 
clues that contribute to a better understanding of both 
the physiological roles of GPR81 and its potential as an 
alternative anti-angiogenic therapeutic target in cancer.
MATERIALS AND METHODS
Cell culture
The breast cancer cell lines MCF7, T47D, MDA-
MB-231, SK-BR-3, MDA-MB-453, MDA-MB-468, 
Figure 7: Schematic overview of GPR81 regulation of breast cancer progression. During breast cancer progression, upregulated 
GPR81 is activated by extracellular lactate, which leads to PI3K/Akt pathway stimulation and the regulation of cell survival. Activation of 
the PI3K/Akt-CREB pathway results in increased AREG production, which AREG promotes neo-vessel formation (angiogenesis) in tumor 
endothelial cells and also provides a proliferative advantage to cancer cells and tumor growth.
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Hs578T and MCF10A were acquired from the American 
Type Culture Collection (ATCC, Manassas, VA, USA), 
where they are regularly authenticated. The cell lines 
were grown at 37°C in 5% CO
2
. Hs578T, MDA-MB-231, 
MDA-MB-453, MDA-MB-468, and SK-BR-3 cells 
were maintained in DMEM (Lonza, Basel, Switzerland) 
containing 10% fetal bovine serum (FBS, Gibco BRL, 
Grand Island, NY, USA), penicillin (100 units/ml; 
Gibco) and streptomycin (100 units/ml, Gibco). MCF7 
and T47D cells were cultured in RPMI 1640 (Lonza), 
10% FBS, penicillin (100 units/ml) and streptomycin 
(100 units/ml). MCF10A cells were cultured in DMEM/
F12 media (1:1) (Invitrogen, Grand Island, NY, USA) 
supplemented with 5% horse serum (Gibco), 10 μg/ml 
bovine insulin (Sigma-Aldrich, St. Louis, MO, USA), 
20 ng/ml epidermal growth factor (EGF; Sigma), 0.5 
μg/ml hydrocortisone (Sigma), 0.1 μg/ml cholera toxin 
(Sigma), penicillin (100 units/ml), and streptomycin 
(100 units/ml). Human umbilical vein endothelial cells 
(HUVECs; Lonza) were maintained in Lonza EGM-MV 
(normal growth medium) at 37°C in 5% CO
2
. The cells 
were maintained in culture plates and used in assays 
between cell passages 3 and 8.
Clinical specimens
The primary tumors analyzed in this study were 
obtained from the Seoul National University College of 
Medicine in compliance with the policies and practices of 
the SNU Internal Review Board. Tumor-adjacent normal 
breast tissue from 20 patients undergoing breast reduction 
surgery and benign or aggressive breast tissue samples 
from 60 patients were collected at the SNU hospital. 
Immediately after biopsy, the tissue samples were frozen 
in liquid nitrogen and stored at -70°C until use.
Mammalian lentiviral shRNAs
MCF7 and T47D cells were infected with a 
recombinant non-replicative lentiviral plasmid (Sigma, 
St. Louis, MO, USA) containing human shGPR81 
(transfected with 2 different shRNA constructs for 
GPR81) or with a control plasmid (pLKO.1-puro) 
obtained from Sigma. Each construct was co-transfected 
with the packaging constructs VSVG (viral glycoprotein 
expression vector) and delta 8.9 (packaging vector) 
packaging constructs. Lentivirus was produced in 293T 
cells using the LipofectAMINE 2000 reagent (Invitrogen, 
Carlsbad, CA, USA). The medium was replaced at 16 h 
after transfection, and the supernatant was harvested after 
an additional 48 h. The lentiviral particles were used to 
transduce the target cells for 24 h. The cells were infected 
with lentivirus (500 μl of supernatant/ml medium) mixed 
with polybrene (4 μg/ml). Puromycin-resistant clones 
(3 μg/ml) were then isolated using the limiting dilution 
method. GPR81 knockdown was verified by RT-PCR and 
Immunocytochemistry.
Cell proliferation assay
An IncuCyte™ Live-cell Imaging System (Essen 
BioScience, Ann Arbor, MI, USA) was used to monitor the 
kinetics of cell growth, as determined by the assessment of 
cell confluency under indicated conditions. Additionally, 
time-lapse phase-contrast images were automatically 
collected once per hour from cells grown for 7 days in 
CO
2
 incubator. Cell growth was quantified and is shown 
as monolayer confluence versus time.
Detection of tumor-derived angiogenic factors 
using antibody arrays
Human angiogenic protein array kit (R&D Systems) 
was used according to the manufacturer’s instructions. 
Briefly, the membranes were blocked, incubated with 100 
μl of conditioned media (CM) overnight, and incubated 
with biotin-conjugated antibodies (1/250) for 2 h and with 
an HRP-linked secondary antibody (1/1000) 30min. Next, 
the membranes were incubated with a chemiluminescent 
substrate and exposed. The reactive proteins were 
visualized and analyzed using an ECL Kit (Thermo 
Scientific, Rockford, IL, USA) and ImageQuant™ 
LAS 4000 (GE Healthcare, Buckinghamshire, UK). 
Quantitative array analysis was performed using Image J 
software.
Tube formation
Pooled HUVECs were purchased from Lonza and 
cultured according to the supplier’s instructions. For the 
Matrigel tube-formation assay, reduced growth factor 
Matrigel™ (BD Biosciences, Bedford, MA, USA) was 
thawed overnight at 4°C. The Matrigel was allowed to 
solidify in 48-well culture dishes at 37°C for 30 min. The 
cells were harvested and seeded at a density of 2×105 cells/
well in the presence or absence of recombinant AREG. 
In separate experiments, the cells were either treated 
with an AREG-neutralizing antibody (R&D Systems, 
Minneapolis, MN) or conditioned medium collected 
from MCF7-shCTL and MCF7-shGPR81 cells. The cells 
were then incubated at 37°C for an additional 12 h. Tube 
formation was observed by capturing images using an 
Olympus CellR microscope. The Matrigel  assay results 
were quantified by measuring the total number of pixels in 
thresholded images using MetaMorph software (Molecular 
Devices, Sunnyvale, CA, USA). Three independent 
experiments were performed, and each experiment was 
performed in triplicate. Student’s t-test was performed to 
determine the significance between the test groups.
Chromatin immunoprecipitation (ChIP) analysis
MCF7-shCTL and MCF7-shGPR81 cells processed 
for ChIP as described previously [44]. Briefly, collected 
cells were treated with 1ml Lysis buffer with protease 
Oncotarget70909www.impactjournals.com/oncotarget
inhibitors (ChIP kit, EMD Millipore, Billerica, MA, USA) 
and were sonicated using the Misonix Sonicator 3000 
(Newton, CT, USA) at high power until DNA fragments 
of 200-1000bp were formed. The sonicated chromatin was 
precipitated using anti-CREB antibody (Cell signaling 
Technology) or rabbit IgG antibody (negative control). 
Precipitated complexes were eluted and treated with 
Proteinase K (100 μg/ml) and DNA fragments were 
purified by Qiagen Quick kit (Qiagen, Hilden Germany). 
The DNA input and comparison between MCF7-shCTL 
and MCF7-shGPR81 cell line as control were used for 
qPCR. The PCR primer of AREG promoter region and 
GAPDH control are listed below (forward, reverse):
Human GAPDH: 5’-AAAAGCGGGAGAAAG 
TAGG-3’, 5’-CTAGCCTCCCGGGTTTCTCT-3’
Human AREG: 5’-TTTTCGGGTAGCACCTTC 
TG-3’, 5’-CAGGTGTGCGAACGTCTGTA-3’
Data was normalized to input DNAs. Differential 
Ct (cycle threshold) values from experimental and input 
DNAs (ΔCt) were used to calculate amplified DNA yield.
Animals and xenograft models
Animal handling and experimentation were 
performed with the approval of the Institutional Animal 
Care and Use Committee of the Ulsan National Institute 
of Science and Technology (UNIST).  6-8 week old 
athymic nu/nu mice (Harlan, Madison, WI, USA) were 
subcutaneously implanted with 17β-estradiol pellets (0.72 
mg, 60-day release; Innovative Research of America, 
Sarasota, FL, USA) before being inoculated with the 
cells. A total of 5×106 MCF7-shCTL or shGPR81 
cells were inoculated into the mammary fat pads of the 
animals (10 per group). The tumor volume was measured 
using a digital slide caliper and was defined as follows: 
(1/2)×(long diameter)×(short diameter)2.
Statistical analyses
Data were analyzed using GraphPad software 
(GraphPad Prism version 7.0 for Windows). All of the 
data measurements are presented as the mean ± SEM. 
Statistical significance was evaluated by the Student’s 
t-test. Values of P<0.05 were considered to be statistically 
significant.
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